Monday, December 20, 2004
World of Pain for a Class of Drugs
"Right now, the COX-2 inhibitor drug market is riddled with uncertainty and in desperate need of pain relief." [TheStreet.com]
skip to main |
skip to sidebar
The Latest News about Defective Pharmaceuticals and Medical Devices. Sponsored by the law firm of Audet & Partners, LLP.
Followers
Blog Archive
-
▼
2004
(93)
-
▼
December
(25)
- Vioxx, Celebrex and Aleve: Ills of a too-free market?
- FDA urges limits on Celebrex, Bextra
- Study halted due to increased heart attacks, strok...
- US regulator calls for limits on use of Celebrex, ...
- Health Canada issues safety information on Vioxx, ...
- EMEA Statement On Valdecoxib (Bextra/Valdyn) & Par...
- Pfizer Suspends Celebrex Advertising
- Merck's shares slide in wake of news report on Vioxx
- World of Pain for a Class of Drugs
- CBS News | Pfizer: Celebrex Poses Heart Risk
- A Brief History of Celebrex and Bextra
- Germans restrict COX-2 inhibitor use
- Essay: We Love Them. We Hate Them. We Take Them.
- Merck to Cut About 5,100 Jobs by Year's End
- Ex-judge says Vioxx probe won't hide facts
- Cummings company revealed Vioxx problems to the na...
- Merck sets up new Vioxx review
- Merck Slashes Its 2005 Estimates on Vioxx
- Cramer: What's going on? Merck execs do not deserv...
- Questions loom over Merck’s severance plan
- Lipitor - Vioxx: Discovering The Statin - Painkill...
- With or Without Vioxx, Drug Ads Proliferate
- Corporate arrogance still rules, despite recent sc...
- UN pricks pharma's conscience
- Study finds risk with Pfizer drug
-
▼
December
(25)
Contact Our Firm
Contact Our Firm
- 1.800.965.1461